ArticleCell reports methods2026
Improved expansion of peripheral blood and iPSC-derived natural killer cells for clinical applications.
Article in Cell reports methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anti-FAP CAR-NK cells as a novel targeted therapy against cervical cancer and cancer-associated fibroblasts.Oncoimmunology · 2025Article
- CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting.Journal of hematology & oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The large-scale expansion of natural killer (NK) cells commonly relies on artificial antigen-presenting cells (aAPCs). Currently, K562 cells expressing 41BBL and membrane-bound IL-21 (mbIL-21) are widely used to expand NK cells for clinical use. Here, we explored whether alternative aAPCs could improve NK cell expansion and better support clinical translation. We developed and tested four genetically modified feeder cell lines as alternative aAPC sources. K562 and 721.221 cells were engineered to express either OX40L or 41BBL, along with mbIL-18/21 and B7H6. We evaluated the expansion of NK cells derived from 3 different sources: unfractionated peripheral blood mononuclear cells (PBMCs), peripheral blood (PB), and induced pluripotent stem cells (iPSCs). Our results showed that 721.221 feeder cells expressing 41BBL-B7H6 or OX40L with mbIL-18/21 significantly enhanced NK cell expansion compared with K562 cell-based aAPCs. All modified aAPCs induced strong NK cell activation and tumor-killing activity. These findings identify 721.221 cell-derived 41BBL-B7H6-mbIL-18/21 cells as promising aAPCs for large-scale NK cell production in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.